Polaryx Therapeutics, Inc.
OperatingBiotech · Paramus, NJ
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Jun 30, 2026| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common stock | 49,845,993 | — | 100.0% | $2.80Sep 2025 |
Shares outstanding over timein today's share terms
Sold to the crowd
- Reg CF · Sep 202516,080 shares at $2.80 in today's terms · sold as 64,321 shares at $0.70; since then a 1-for-4 reverse split (Jan 2026)$45K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
1 personNames and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 1 annual reports (FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form 10-QAug 13, 20260001213900-26-089118EDGAR
- Form 10-QMay 15, 20260001213900-26-056973EDGAR
- Form 10-KMar 24, 20260001213900-26-033064EDGAR
- Form C-UOct 31, 20250001213900-25-104723EDGAR
- Form C-UOct 27, 20250001213900-25-102529EDGAR
- Form C/AOct 1, 20250001213900-25-094743EDGAR
- Form CSep 3, 20250001213900-25-084152EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.